...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Top-line vs. Full Detailed Clinical Trial Results

It would be a real “ultra heartbreaker” if we had a repeat performance of June 2013 in which we didn’t meet an endpoint....don’t even want to imagine this possiblility....it is puzzling to me the “drip, drip, drip” that we’ve been getting since Sept 10, 2018.

Would love to see us just “hang in there” at $2.50 American....will be happy with this number all the way thru the end of February 2019.

I will continue to stay positive....this stock has just got to be the greatest thing that happened in bio tech for years, along with Zenith!

Share
New Message
Please login to post a reply